Matthew Lindquist, Brooke Sweeney
Despite increasing recognition of pediatric obesity as a chronic disease, many clinicians continue to rely on "watchful waiting," assuming pubertal growth will mitigate excess weight and metabolic risk. Current evidence contradicts this approach. Children under 12 years of age with obesity frequently demonstrate clinically significant metabolic disease, including insulin resistance, dyslipidemia, dysglycemia, and metabolic dysfunction-associated steatotic liver disease (MASLD), often before symptoms emerge. Puberty does not reverse these processes; rather, physiologic pubertal insulin resistance amplifies preexisting metabolic dysfunction and accelerates disease progression. Delayed intervention allows potentially irreversible injury during a critical period of metabolic plasticity. This article reviews contemporary biologic and longitudinal data challenging the pubertal correction paradigm, highlights the concept of metabolic memory, and discusses limitations of lifestyle-only interventions. Drawing parallels to integrated pediatric mental health care, we propose a primary care- centered model emphasizing earlier metabolic screening, coordinated multidisciplinary care, and timely intervention to improve long-term cardiometabolic outcomes.